

Announcement of the results of the MONALEESA-7 clinical study

The Ministry of Health has approved Ribociclib for the treatment of advanced breast cancer patients under the age of 45. Ribociclib can be used in combination with an aromatase inhibitor as first-line therapy for all women with HR-positive, HER2-negative advanced or metastatic breast cancer. Breast cancer is the second most common cancer in Egypt. About 50% of breast cancer patients are under 50 years old.